专题综述:药物抵抗基因研究  

Genetic Polymorphisms and Antiplatelet Drug Individualized Treatment

作　　者：邵渊[1] 丁红[2] 徐运[1] 

机构地区：[1]南京大学医学院附属鼓楼医院神经科,南京210008 [2]南京医科大学第二附属医院神经科

出　　处：《中国卒中杂志》2014年第4期309-316,共8页Chinese Journal of Stroke

摘　　要：血小板的活化与聚集在血栓形成的病理生理中起着重要的作用，而抗血小板治疗是动脉硬化性脑梗死急性期治疗、一级及二级预防的重要组成部分。目前阿司匹林、氯吡格雷为最常用的抗血小板药物。但抗血小板药物对不同人群血小板抑制作用存在较大差异，人群对抗血小板药物的低反应性与缺血性脑血管病复发具有相关性，本篇将重点从基因多态性的角度阐述抗血小板药物抵抗的可能机制，指导临床个体化治疗。Platelet activation and aggregation play a crucial role in the pathophysiology of atherothrombosis. Aspirin and clopidogrel have become common drugs in treating and preventing ischemic stroke by inhibiting platelet activation and aggregation. There is a great difference of antiplatelet drugs＆#39; inhibition effects on platelet aggregation in individual patients. Resistance on anti-platelet drugs could increase risk of stroke relapse. The exact mechanism of variable response to antiplatelet drugs is still unclear. Multiple potential mechanisms have been proposed. In this article, we will discuss the genetic polymorphisms and antiplatelet drug resisitance, in order to guide individualized treatment.

关 键 词：阿司匹林 氯吡格雷 抵抗 基因多态性 

分 类 号：R973.2[医药卫生—药品]